Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Validating enhanced oncolytic farmington viruses for the treatment of glioblastoma multiforme

EF 2013-14

Résumé
Glioblastoma multiforme (GBM) is the most common type of brain cancer in adults. Despite aggressive radiation and chemotherapy, patient survival is grim and the cancer ultimately recurs in most patients. This cancer also readily develops resistance to standard treatments and metastasizes to other areas of the body. It is apparent that new treatment options are needed for GBM patients. In the past few years, oncolytic viruses (OVs) have shown great promise as newcomers to the cancer treatment field. OVs are viruses that selectively destroy tumor cells while sparing normal cells. Their cancer killing abilities, as well as their specificity for cancer cells, can easily be improved via genetic manipulation. However, there has not been an effective, safe OV developed for the treatment of brain cancers. Our lab (Stojdl) aims to define and identify effective variants of the recently described Farmington virus (FMT) to treat brain cancers. FMT was discovered as a potent anti-cancer agent during a screening process performed by the Stojdl lab. It was found that not only is the virus good at killing many types of cancer, it is also non-toxic to normal human tissue samples and is safe to use in animal models. In order to maximize the cancer killing ablility of FMT, the Stojdl lab genetically engineered several FMT variants that express factors to enhance cancer cell death. The objective of the project described here is to evaluate these new FMT variants in several different mouse models of brain cancer. The end goal is to select the best candidate for non-human primate testing, ideally leading us to an eventual clinical trial. Overall animal survival and the immune system’s response to the virus and to the tumor will be used to decide which FMT variant has the most potential. The project will also investigate which delivery method is best for the FMT variant (intravenous or directly into the brain). Finally, the project will look into whether or not this FMT variant can be combined with currently approved drugs to even further improve treatment outcomes. We have outlined a logical approach to developing a new class of brain-safe, tumor-selective OVs based on FMT. The proposal builds upon a solid foundation of preliminary findings that can lead to better treatment options for GBM patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
311931
Name
Rowe Katelynn
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Validating enhanced oncolytic farmington viruses for the treatment of glioblastoma multiforme
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Apoptosis; Cytotoxicity; Efficacy; Farmington Virus; Glioblastoma Multiforme; Immunomodulation; Non-Neurotoxic; Oncolysis; Safety; Transgenes
Abstract
Glioblastoma multiforme (GBM) is the most common type of brain cancer in adults. Despite aggressive radiation and chemotherapy, patient survival is grim and the cancer ultimately recurs in most patients. This cancer also readily develops resistance to standard treatments and metastasizes to other areas of the body. It is apparent that new treatment options are needed for GBM patients. In the past few years, oncolytic viruses (OVs) have shown great promise as newcomers to the cancer treatment field. OVs are viruses that selectively destroy tumor cells while sparing normal cells. Their cancer killing abilities, as well as their specificity for cancer cells, can easily be improved via genetic manipulation. However, there has not been an effective, safe OV developed for the treatment of brain cancers. Our lab (Stojdl) aims to define and identify effective variants of the recently described Farmington virus (FMT) to treat brain cancers. FMT was discovered as a potent anti-cancer agent during a screening process performed by the Stojdl lab. It was found that not only is the virus good at killing many types of cancer, it is also non-toxic to normal human tissue samples and is safe to use in animal models. In order to maximize the cancer killing ablility of FMT, the Stojdl lab genetically engineered several FMT variants that express factors to enhance cancer cell death. The objective of the project described here is to evaluate these new FMT variants in several different mouse models of brain cancer. The end goal is to select the best candidate for non-human primate testing, ideally leading us to an eventual clinical trial. Overall animal survival and the immune system’s response to the virus and to the tumor will be used to decide which FMT variant has the most potential. The project will also investigate which delivery method is best for the FMT variant (intravenous or directly into the brain). Finally, the project will look into whether or not this FMT variant can be combined with currently approved drugs to even further improve treatment outcomes. We have outlined a logical approach to developing a new class of brain-safe, tumor-selective OVs based on FMT. The proposal builds upon a solid foundation of preliminary findings that can lead to better treatment options for GBM patients.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rowe, Katelynn
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~